CN
Search Within
1011007
Applied Filters:
Keyword:'1011007'
Showing 1-22 of 22 results for "1011007" within Papers
Jennifer Hayes et al.
Journal of drugs in dermatology : JDD, 10(4), 409-412 (2011-04-02)
The potential relationship between systemic retinoids used in dermatology and affective disorders is controversial. Acitretin, which is widely used in the treatment of psoriasis is part of this controversy secondary to its chemical relation to isotretinoin, a drug which has
Mei-Lin Pang et al.
Expert opinion on drug metabolism & toxicology, 4(7), 953-964 (2008-07-16)
Acitretin is a systemic retinoid used for psoriasis. It normalizes cellular differentiation and maturation and is also used as a chemopreventive agent against cutaneous malignancies. However, it is not used frequently because of its side-effect profile. Safety and efficacy of
Mariëlle Te Booij et al.
The Journal of dermatological treatment, 22(2), 86-89 (2010-08-03)
Acitretin is a time-honored treatment for psoriasis. During the last decade biologics have revolutionized the treatment of psoriasis. This raises the question: What is the position of acitretin as a classical systemic treatment for psoriasis in the era of biologics?
G Carretero et al.
Actas dermo-sifiliograficas, 104(7), 598-616 (2013-07-31)
Phototherapy, classic systemic treatments (methotrexate, acitretin, and ciclosporin), and biologic agents (etanercept, infliximab, adalimumab, and ustekinumab) constitute a broad therapeutic arsenal that increases the likelihood of achieving control of severe and extensive disease in patients with psoriasis. Acitretin continues to
M M Tang et al.
Dermatology (Basel, Switzerland), 225(4), 338-343 (2013-01-25)
Generalized pustular psoriasis (GPP) is a severe inflammatory disease characterized by recurrent eruptions of sterile pustules on erythematous skin. Although tumor necrosis factor (TNF) antagonists may lead to a rapid resolution of GPP, the mechanism of action of these agents
M Lebwohl et al.
The Journal of dermatological treatment, 14 Suppl 2, 3-6 (2003-10-28)
Retinoids have been used for the treatment and suppression of cutaneous malignancies in patients with basal cell nevus syndrome, xeroderma pigmentosum, and in patients with recurrent skin cancers as a result of immunosuppression for renal transplantation. We report a 40-year-old
Dilek Seckin et al.
The Australasian journal of dermatology, 50(3), 214-216 (2009-08-08)
Drug-induced hair colour and texture changes have been reported rarely. We describe a 70-year-old woman with psoriasis who noticed darkening of her previously white hair, which also gained a curly appearance after 6 months of acitretin treatment. We present this
Evidence based or theoretical concern? Pseudotumor cerebri and depression as acitretin side effects.
John Starling et al.
Journal of drugs in dermatology : JDD, 4(6), 690-696 (2005-11-24)
Oral retinoids are among the first line agents for treatment of pustular and erythrodermic psoriasis, and they are effective in combination with phototherapy and other topical and systemic agents for the treatment of plaque psoriasis. Acitretin is the leading oral
Junko Takeshita et al.
Journal of the American Academy of Dermatology, 71(6), 1167-1175 (2014-09-28)
The effectiveness of psoriasis therapies in real-world settings remains relatively unknown. We sought to compare the effectiveness of less commonly used systemic therapies and commonly used combination therapies for psoriasis. This was a multicenter cross-sectional study of 203 patients with
Chai Sue Lee et al.
Expert opinion on pharmacotherapy, 6(10), 1725-1734 (2005-08-10)
Acitretin is a second-generation, systemic retinoid that has been approved for the treatment of psoriasis since 1997. It can be considered one of the treatments of choice for pustular and erythrodermic psoriasis. However, the efficacy of acitretin as a monotherapy
Chai Sue Lee et al.
Expert opinion on drug safety, 8(6), 769-779 (2009-12-10)
Acitretin is an oral retinoid that is approved for the treatment of psoriasis. It is unique compared to other systemic therapies for psoriasis such as methotrexate and cyclosporine in that it is not immunosuppressive. It is, therefore, safe for use
Successful treatment of harlequin ichthyosis with acitretin.
S Singh et al.
International journal of dermatology, 40(7), 472-473 (2001-10-27)
Agranulocytosis and total scalp alopecia following acitretin.
T A Chave et al.
The British journal of dermatology, 148(5), 1063-1064 (2003-06-06)
Alessandro Borghi et al.
Acta dermato-venereologica, 95(3), 332-336 (2014-07-01)
The efficacy and safety of acitretin was evaluated retrospectively in a cohort of 46 patients with moderate to severe plaque psoriasis (Psoriasis Area and Severity Index (PASI) range 10-42). Patients were treated at an initial dose of 10 mg/day acitretin
British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology.
A D Ormerod et al.
The British journal of dermatology, 162(5), 952-963 (2010-04-29)
M Lebwohl et al.
Journal of the American Academy of Dermatology, 45(4), 544-553 (2001-09-25)
Although adjunctive treatment with retinoids in concert with either psoralen-ultraviolet A (PUVA) or ultraviolet B (UVB) phototherapy has been a treatment option for chronic, moderate to severe plaque psoriasis for nearly two decades, acitretin-UV therapy is an underutilized therapeutic modality.
Rashmi Sarkar et al.
Indian journal of dermatology, venereology and leprology, 79(6), 759-771 (2013-11-02)
Acitretin, a synthetic retinoid has gradually replaced etretinate in today's dermatologic practice because of its more favorable pharmacokinetics. Acitretin over the past 20 years has proven useful in a number of difficult-to-treat hyperkeratotic and inflammatory dermatoses and nonmelanoma skin cancers.
A Hernández-Núñez et al.
Clinical and experimental dermatology, 26(3), 256-259 (2001-06-26)
We report a patient who presented with an intensely pruritic rash, with hyperpigmentation of the whole back and multiple hyperpigmented and hyperkeratotic papules over his forearms and lower extremities. Histologically, he showed deposits of amyloid that reacted positively with monoclonal
Taru Garg et al.
Dermatology online journal, 17(5), 3-3 (2011-06-04)
Linear porokeratosis is a rare disorder of keratinization that usually presents at birth. We report a 17-year-old male with generalized linear porokeratosis, a very rare variant of porokeratosis, with extensive involvement of the trunk and extremities along with nail and
Christoffer Ingves et al.
Scandinavian journal of plastic and reconstructive surgery and hand surgery, 37(5), 293-295 (2003-12-03)
We report the successful outcome of treatment of a basal cell carcinoma (BCC) with topical imiquimod and systemic acitretin in a 48-year-old woman. We think that this treatment is a possible option for management of these non-life-threatening tumours. Experimental evidence
Lauren K Dunn et al.
Journal of drugs in dermatology : JDD, 10(7), 772-782 (2011-07-02)
Acitretin is a systemic retinoid drug used in the treatment of severe psoriasis. It has also been used for a spectrum of other difficult-to-treat dermatoses, including hyperkeratotic and inflammatory dermatoses and non-melanoma skin cancers. Here we review the available data
F Aydin et al.
Clinical and experimental dermatology, 32(6), 683-686 (2007-08-24)
Keratoacanthoma centrifugum marginatum (KCM) is a rare entity, usually classified as solitary keratoacanthoma (KA). The Ferguson-Smith type is the most common form of multiple KAs. Because development of multiple KAs and KCM in a single patient has rarely been reported
Page 1 of 1